Pharmaceutical Research and Risk Europe 
22nd – 23rd March 2011
London, UK

Optimisation and Risk assessment in the European R&D market

Over two days you will learn…

• How to adapt to the changing practices in the biopharmaceutical industry
• The financial challenges and it’s impact on the biotech industry
• Pipeline development opportunities – reformulation and redevelopment
• Potential ROI with drug reformulation technologies
• Effectively extending the lifecycle of patented drugs through novel formulation technologies
• Risk assessment for cost effective pipeline development
• The challenges faced by pressures from Government for “value for money”

Conference Background:

The pharmaceutical is under increasing strain, with pipelines shrinking, funding drying up, pressures from Governments to deliver more “cost effective drugs” and a lack of new candidates the industry needs to start working smarter not harder.

Over two days Pharmaceutical Research and Risk Europe will cover the major challenges faced and some of the potential solutions.  Key areas to addressed include; the potential for drug redevelopment and reformulation. With an active generics market now is the time to take advantage of drug reformulation to increase your portfolio.

Over the two days we will also cover Process development, optimisation, risk assessment and new strategies need to be implemented in order to develop R&D pipelines. Pipeline development is key to ensure the ongoing success of any pharmaceutical company.

With over 100 senior level piers attending Pharmaceutical Research and Risk Europe, don't miss this great opportunity to discuss, debate and reach conclusions on the areas that matter to you.